Cencora Inc
NYSE:COR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Cencora Inc
EPS (Diluted)
Cencora Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Cencora Inc
NYSE:COR
|
EPS (Diluted)
$8
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
17%
|
|
|
Cardinal Health Inc
NYSE:CAH
|
EPS (Diluted)
$7
|
CAGR 3-Years
N/A
|
CAGR 5-Years
8%
|
CAGR 10-Years
5%
|
|
|
Henry Schein Inc
NASDAQ:HSIC
|
EPS (Diluted)
$3
|
CAGR 3-Years
-6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
1%
|
|
|
Adapthealth Corp
NASDAQ:AHCO
|
EPS (Diluted)
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
Patterson Companies Inc
NASDAQ:PDCO
|
EPS (Diluted)
$1
|
CAGR 3-Years
-3%
|
CAGR 5-Years
25%
|
CAGR 10-Years
-3%
|
|
|
Mckesson Corp
NYSE:MCK
|
EPS (Diluted)
$35
|
CAGR 3-Years
16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
15%
|
|
Cencora Inc
Glance View
Cencora Inc., once known as AmerisourceBergen, stands as a pivotal player in the healthcare landscape, sculpting pathways for the seamless distribution of pharmaceuticals across the globe. Born from a merger of AmeriSource Health Corporation and Bergen Brunswig Corporation in 2001, the company carved its identity by building extensive networks that bind drug manufacturers, pharmacies, and healthcare providers together into a cohesive chain. This intricate web ensures that pharmaceutical products, ranging from common prescriptions to specialized drugs, reach their destinations efficiently and securely. Cencora's proficiency lies not just in logistics but in its ability to adapt and innovate within rigid regulatory frameworks, ensuring its clients navigate the complexities of compliance while focusing on patient care. In terms of profitability, Cencora thrives on its vast and exponentially growing distribution channels, earning a steady stream of revenue through service fees and percentage fees tied to the value of distributed goods. Moreover, the company's integrated service offerings, such as consulting, analytics, and supply chain management solutions, provide additional avenues of income by addressing the strategic needs of its clientele. This dual approach of logistics and consultancy allows Cencora not only to serve as a conduit for drug distribution but also as a trusted advisor in a healthcare sphere that is increasingly data-driven and efficiency-focused. Through its multi-faceted business model, Cencora secures its foundation in a volatile industry, supporting the balance of patient needs, market demands, and regulatory compliance.
See Also
What is Cencora Inc's EPS (Diluted)?
EPS (Diluted)
8.3
USD
Based on the financial report for Dec 31, 2025, Cencora Inc's EPS (Diluted) amounts to 8.3 USD.
What is Cencora Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
17%
Over the last year, the EPS (Diluted) growth was 16%.